reports
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that it has filed a final short form base shelf prospectus (the “Base Shelf Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”) on September 26, 2025 (the “Effective Date”). The Base Shelf Prospectus allows Spectral to qualify the d...
Spectral Medical Announces Publication of EDEN Observational Study
Spectral Medical Announces Publication of EDEN Observational Study New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today highlighted newly published findings in Critical Care Explorations that define endotoxic septic shock (“ESS”) as a distinct and deadly form of septic shock. The prospective, multicent...
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago Septembe...
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025 Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its sponsorship of the Unite for Sepsis Symposium, taking place September 8 – 9, 2025, in Chicago, Illinois. The Company also announced that Debra Foster, Clinical Consultant at Spectral Medical, will participate in a feat...
Spectral Medical Receives US$3 Million From Vantive
Spectral Medical Receives US$3 Million From Vantive TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B advance from Vantive US Healthcare LLC (“Vantive”) pursuant to the previously disclosed senior secured promissory note entered into in May 2025. The Tranche B advance further strengthens Spectral’s balance sheet and will be used to support ongoing regulatory and commercializatio...
Spectral Medical and Vantive Announce Topline Results from Spectral’s ...
Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99% posterior probability of benefit 38.7% Mortality at 28 days with PMX confirms results of prior trial subset TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectra...
Spectral Medical Announces Second Quarter and Provides Corporate Updat...
Spectral Medical Announces Second Quarter and Provides Corporate Update Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter and provided a corporate update. The second quarter of 2025 marked significant clinical and operational progress for Spectral. Following the completion of patient enrollment in the Tigris tri...
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”). The base shelf prospectus, when made final, will allow Spectral to qualify the distribution by way of a prospectus of up to $1...
Spectral Medical Inc. Announces Results of Annual Meeting of Sharehold...
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved. Results of the matte...
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConn...
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York. Investors interested in scheduling a meeting with the C...
Spectral Medical Announces First Quarter and Provides Corporate Update
Spectral Medical Announces First Quarter and Provides Corporate Update Tigris Trial Enrollment completedTopline results expected to be released in August 2025Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter and provided a corporate update. ...
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million...
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive • Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has entered into a senior secured promis...
Spectral Medical Completes Tigris Trial Enrollment
Spectral Medical Completes Tigris Trial Enrollment 157 patients enrolledTopline results expected to be released in August 2025Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the completion of full enrollment in the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults ...
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and ...
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update 154 patients enrolled TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2024 and provided a corporate update. The Company made significant progress throughout 2024, both clinically and operationally. Specifically, regarding its Tigris trial, a P...
Spectral Medical Provides February Tigris Trial Update
Spectral Medical Provides February Tigris Trial Update 152 patients enrolled TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Strong start to 2025 enrollment: 152 patients...
Spectral Medical Provides January Tigris Trial Update
Spectral Medical Provides January Tigris Trial Update Strong enrollment activity to start 2025146 patients enrolled TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Strong start to 2025 enrollment: 14...
Spectral Medical Provides December Tigris Trial Update
Spectral Medical Provides December Tigris Trial Update • 140 patients enrolled TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Strong close to 2024 enrollment with 140 patients enrolled at end of Dec...
Spectral Medical Provides November Tigris Trial Update
Spectral Medical Provides November Tigris Trial Update • 136 patients enrolled • Company to host Tigris Trial Update Call December 16, 2024 TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: 136 pati...
Spectral Medical Announces Third Quarter Results and Provides Corporat...
Spectral Medical Announces Third Quarter Results and Provides Corporate Update Tigris Trial Enrollment at 135 PatientsStrengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter ended September 30, 2024, and provided a corporate update. Spectral has continued its significant progress throughout the third quart...
Spectral Medical Provides October Tigris Trial Update
Spectral Medical Provides October Tigris Trial Update • 135 patients enrolled TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment continues for 2024: 135 patients enrolled at end of Oct...
Spectral Medical Provides September Tigris Trial Update
Spectral Medical Provides September Tigris Trial Update • 132 patients enrolled TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment continues for 2024: 132 patients enrolled at en...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.